The 2012 Annual Meeting of Shareholders of Protalix BioTherapeutics, Inc. (the "Company") was held on June 17, 2012. Holders of 55.5% of our outstanding shares of common stock entitled to vote as of the record date for the meeting participated in person or by proxy.

The matters voted upon at the meeting are set forth below including the number of votes cast for, number of votes cast against or withheld, as applicable, the number of abstentions, the number of broker non-votes and other applicable votes with respect to each such matter.

(1) Election of Directors

                                         For     Withheld    Broker
                                                           Non-Votes
             Zeev Bronfeld            39,007,328  543,111  11,407,452
             David Aviezer, Ph.D.     39,019,328  531,111  11,407,452
             Yoseph Shaaltiel, Ph.D.  36,315,855 3,234,584 11,407,452
             Alfred Akirov            36,543,151 3,007,288 11,407,452
             Amos Bar Shalev          36,554,651 2,995,788 11,407,452
             Yodfat Harel Buchris     36,541,730 3,008,709 11,407,452

(2) Approval of an amendment to the Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan to increase the number of shares of common stock available under the plan from 9,741,655 shares to 11,341,655 shares

For Against Abstain Broker Non-Votes 24,467,193 12,755,334 2,327,912 11,407,452

(3) Approval, on a non-binding, advisory basis, the compensation of the Company's named executive officers

For Against Abstain Broker Non-Votes 33,683,299 575,019 5,292,121 11,407,452

(4) Ratification of appointment of Kesselman & Kesselman

For Against Abstain Broker Non-Votes 50,336,871 161,639 459,381 --